127 related articles for article (PubMed ID: 22231447)
1. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
Li X; Lu Y; Liang K; Hsu JM; Albarracin C; Mills GB; Hung MC; Fan Z
Oncogene; 2012 Oct; 31(40):4372-83. PubMed ID: 22231447
[TBL] [Abstract][Full Text] [Related]
2. BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
Miah S; Goel RK; Dai C; Kalra N; Beaton-Brown E; Bagu ET; Bonham K; Lukong KE
PLoS One; 2014; 9(2):e87684. PubMed ID: 24523872
[TBL] [Abstract][Full Text] [Related]
3. BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential.
Miah S; Banks CAS; Ogunbolude Y; Bagu ET; Berg JM; Saraf A; Tettey TT; Hattem G; Dayebgadoh G; Kempf CG; Sardiu M; Napper S; Florens L; Lukong KE; Washburn MP
Sci Adv; 2019 Oct; 5(10):eaaw3113. PubMed ID: 31681835
[TBL] [Abstract][Full Text] [Related]
4. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
[TBL] [Abstract][Full Text] [Related]
5. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.
Iida M; Brand TM; Campbell DA; Li C; Wheeler DL
Oncogene; 2013 Feb; 32(6):759-67. PubMed ID: 22430206
[TBL] [Abstract][Full Text] [Related]
6. HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion.
Pires IM; Blokland NJ; Broos AW; Poujade FA; Senra JM; Eccles SA; Span PN; Harvey AJ; Hammond EM
Cancer Biol Ther; 2014 Oct; 15(10):1350-7. PubMed ID: 25019382
[TBL] [Abstract][Full Text] [Related]
7. Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.
Al-Aidaroos AQ; Yuen HF; Guo K; Zhang SD; Chung TH; Chng WJ; Zeng Q
J Clin Invest; 2013 Aug; 123(8):3459-71. PubMed ID: 23867504
[TBL] [Abstract][Full Text] [Related]
8. Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor.
Weitsman G; Mitchell NJ; Evans R; Cheung A; Kalber TL; Bofinger R; Fruhwirth GO; Keppler M; Wright ZVF; Barber PR; Gordon P; de Koning T; Wulaningsih W; Sander K; Vojnovic B; Ameer-Beg S; Lythgoe M; Arnold JN; Årstad E; Festy F; Hailes HC; Tabor AB; Ng T
Oncogene; 2017 Jun; 36(25):3618-3628. PubMed ID: 28166195
[TBL] [Abstract][Full Text] [Related]
9. Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Tsui T; Miller WT
Biochemistry; 2015 May; 54(20):3173-82. PubMed ID: 25940761
[TBL] [Abstract][Full Text] [Related]
10. Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.
Chastkofsky MI; Bie W; Ball-Kell SM; He YY; Tyner AL
J Invest Dermatol; 2015 Oct; 135(10):2492-2501. PubMed ID: 25938342
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-anilino α-carbolines as novel Brk inhibitors.
Mahmoud KA; Krug M; Wersig T; Slynko I; Schächtele C; Totzke F; Sippl W; Hilgeroth A
Bioorg Med Chem Lett; 2014 Apr; 24(8):1948-51. PubMed ID: 24650640
[TBL] [Abstract][Full Text] [Related]
12. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
Ai M; Qiu S; Lu Y; Fan Z
Cell Signal; 2013 Sep; 25(9):1754-61. PubMed ID: 23707532
[TBL] [Abstract][Full Text] [Related]
13. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Ai M; Liang K; Lu Y; Qiu S; Fan Z
Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
[TBL] [Abstract][Full Text] [Related]
14. Potential of targeting signal-transducing adaptor protein-2 in cancer therapeutic applications.
Maemoto T; Sasaki Y; Okuyama F; Kitai Y; Oritani K; Matsuda T
Explor Target Antitumor Ther; 2024; 5(2):251-259. PubMed ID: 38745775
[TBL] [Abstract][Full Text] [Related]
15. The Role of Autophagy in Human Uveal Melanoma and the Development of Potential Disease Biomarkers and Novel Therapeutic Paradigms.
Wang JZ; Paulus P; Niu Y; Zhu L; Morisseau C; Rawling T; Murray M; Hammock BD; Zhou F
Biomedicines; 2024 Feb; 12(2):. PubMed ID: 38398064
[TBL] [Abstract][Full Text] [Related]
16. An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC.
Huang Y; Cuan X; Zhu W; Yang X; Zhao Y; Sheng J; Zi C; Wang X
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762316
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Potential of Protein Tyrosine Kinase 6 in Colorectal Cancer.
Jerin S; Harvey AJ; Lewis A
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509364
[TBL] [Abstract][Full Text] [Related]
18. PTK6 inhibits autophagy to promote uveal melanoma tumorigenesis by binding to SOCS3 and regulating mTOR phosphorylation.
Liu B; Yao X; Zhang C; Liu Y; Wei L; Huang Q; Wang M; Zhang Y; Hu D; Wu W
Cell Death Dis; 2023 Jan; 14(1):55. PubMed ID: 36690663
[TBL] [Abstract][Full Text] [Related]
19. Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance.
Hashimoto S; Hashimoto A; Muromoto R; Kitai Y; Oritani K; Matsuda T
Cells; 2022 Aug; 11(16):. PubMed ID: 36010693
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
